Treatment of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia: Retrospective Comparison between Intravenous Colistin and Intravenous AmpicillinSulbactam

American Journal of Therapeutics

Volumn 23, Issue 1, 2016, Pages e78-e85

  Zalts, Ronen ^a   Neuberger, Ami ^b,c   Hussein, Khetam ^b   Raz Pasteur, Ayelet ^b,d   Geffen, Yuval ^e   Mashiach, Tanya ^b   Finkelstein, Renato ^b  

^a Rambam Health Care Campus ^*  (Israel)

^b Unit of Infectious Diseases   (Israel)

^c Rambam Health Care Campus   (Israel)

^d Internal Medicine C   (Israel)

^e Microbiology Laboratory   (Israel)

Author keywords

ampicillinsulbactam; carbapenem resistant Acinetobacter baumannii; colistin; treatment; ventilator associated pneumonia

Indexed keywords

CARBAPENEM; COLISTIN; CREATININE; SULTAMICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; SULBACTAM;

ACINETOBACTER BAUMANNII; ACUTE KIDNEY FAILURE; ADULT; APACHE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; HEMODIALYSIS; HUMAN; INTENSIVE CARE; KIDNEY FUNCTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MORTALITY RATE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; TRACHEAL ASPIRATION PROCEDURE; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA; AGED; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED;

ACINETOBACTER BAUMANNII; ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AMPICILLIN; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; RETROSPECTIVE STUDIES; SULBACTAM;

EID: 84955747361     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3182a32df3     Document Type: Article

References (37)

1. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis. 2010;23:332-339.
2. Paul M,WeinbergerM, Siegman-Igra Y, et al. Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997-2002. J Hosp Infect. 2005;60:256-260.
3. Gilad J, Carmeli Y. Treatment options for multidrugresistant Acinetobacter species. Drugs. 2008;68:165-189.
4. Abbo A, Carmeli Y, Navon-Venezia S, et al. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis. 2007;26:793-800.
5. Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest. 2010;138:1333-1339.
6. Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54:1720-1726.
7. Vicari G, Bauer SR, Neuner EA, et al. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis. 2013;56:398-404.
8. Kwon JA, Lee JE, Huh W, et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents. 2010;35:473-477.
9. Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med. 2010;25:343-348.
10. Betrosian AP, Frantzeskaki F, Xanthaki A, et al. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect. 2008;56:432-436.
11. Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med. 2007;33:1162-1167.
12. Rios FG, Luna CM, Maskin B, et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J. 2007;30:307-313.
13. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenemsusceptible VAP. Clin Infect Dis. 2003;36:1111-1118.
14. Rigatto MH, Ribeiro VB, Konzen D, et al. Comparison of polymyxin B with other antimicrobials in the treatment of ventilator-associated pneumonia and tracheobronchitis caused by Pseudomonas aeruginosa or Acinetobacter baumannii. Infection. 2013;41:321-328.
15. Yahav D, Farbman L, Leibovici L, et al. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect. 2012; 18:18-29.
16. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated pneumonia. Am J Respir Crit Care Med. 2005; 171:388-416.
17. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40: 373-383.
18. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-829.
19. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsisrelated Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996; 22:707-710.
20. Murray PR, Baron EJ, Pfaller MA, et al. Manual of Clinical Microbiology. 8th ed. Washington, DC: ASM Press; 2003.
21. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement. M100-S20. Wayne, PA: CLSI; 2010.
22. Micromedex- Healthcare Series [Internet database]. Greenwood Village, CO: Thompson Healthcare. 2009, updated 2013.
23. Ioanas M, Ferrer M, Cavalcanti M, et al. Causes and predictors of nonresponse to treatment of the ICUacquired pneumonia. Crit Care Med. 2004;32:938-945.
24. Higgins PG, Dammhayn C, Hackel M, et al. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2010;65:233-238.
25. Mezzatesta ML, Trovato G, Gona F, et al. In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy. Ann Clin Microbiol Antimicrob. 2008;7:4.
26. Punpanich W, Munsrichoom A, Srisarang S, et al. In vitro activities of colistin and ampicillin/sulbactam against Acinetobacter baumannii. J Med Assoc Thai. 2011;94:S95-S100.
27. Docobo-Perez F, Nordmann P, Domínguez-Herrera J, et al. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli. Int J Antimicrob Agents. 2012;39:251-254.
28. Montero A, Ariza J, Corbella X, et al. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2002;46:1946-1952.
29. Levin AS, Barone AA, Penço J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrugresistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999;28:1008-1011.
30. Reina R, Estenssoro E, Sáenz G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med. 2005;31: 1058-1065.
31. Koomanachai P, Tiengrim S, Kiratisin P, et al. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis. 2007;11:402-406.
32. Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother. 2010;65:1019-1027.
33. Holloway KP, Rouphael NG, Wells JB, et al. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother. 2006;40:1939-1945.
34. Falagas ME, Rafailidis PI, Kasiakou SK, et al. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistinmeropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect. 2006;12:1227-1230.
35. Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care. 2003;7:R78-R83.
36. Michalopoulos AS, Tsiodras S, Rellos K, et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect. 2005;11:115-121.
37. Bergen PJ, Li J, Nation RL. Dosing of colistin-back to basic PK/PD. Curr Opin Pharmacol. 2011;11:464-469.